Results 131 to 140 of about 675 (153)

Afamelanotide for the treatment of erythropoietic protoporphyria

Expert Opinion on Orphan Drugs, 2013
Introduction: Erythropoietic protoporphyria (EPP) is characterized by incapacitating pain in the sunlight-exposed skin areas due to accumulation of the metabolite protoporphyrin. Until now, no effective prevention of phototoxicity has been available. Afamelanotide, an α-melanocyte-stimulating hormone (α-MSH) analogue and first-in-class drug, induces ...
openaire   +1 more source

Afamelanotide

Reactions Weekly, 2011
  +5 more sources

Afamelanotide in managing cutaneous phototoxicity in erythropoietic protoporphyria: a Scottish perspective

Clinical and Experimental Dermatology
Erythropoietic protoporphyria (EPP) is a rare but severely debilitating photodermatosis triggered by exposure to visible and longwave ultraviolet A light, causing intense and prolonged pain that leads to extreme sunlight avoidance and a markedly reduced quality of life.
Robert S Dawe, Alastair Kerr, Ewan Eadie, Suzanne Waterston, Marese O’Reilly, Victoria A McGuire   +5 more
openaire   +1 more source

A review and update on melanocyte stimulating hormone therapy: afamelanotide.

Journal of drugs in dermatology : JDD, 2014
Afamelanotide ([Nle4-D-Phe7]-alpha-MSH) is an analog of alpha-melanocyte stimulating hormone given as a subcutaneous injection. Afamelanotide is currently undergoing phase II and III trials in Europe and the US for skin diseases including vitiligo, erythropoietic protoporphyria, polymorphic light eruption and prevention of actinic keratoses in organ ...
Jordan, Fabrikant, Khasha, Touloei, Stuart M, Brown   +2 more
openaire   +1 more source

Afamelanotide

Reactions Weekly, 2013
openaire   +2 more sources

Afamelanotide in the Treatment of Dermatologic Disease

Skin therapy letter
Afamelanotide, an α-melanocyte stimulating hormone analogue, has become an emerging therapeutic option for a variety of skin conditions previously refractory to other treatments. Its efficacy has been demonstrated in several dermatologic conditions, including erythropoietic protoporphyria (EPP), solar urticaria, polymorphic light eruption (PMLE ...
Morgan M, McNeil, Amanda F, Nahhas, Taylor L, Braunberger, Iltefat H, Hamzavi   +3 more
openaire   +1 more source

Afamelanotide

Reactions Weekly, 2009
openaire   +1 more source

Clinical Experience with Afamelanotide for the Protoporphyrias in the United States

Blood, 2022
Rebecca Karp Leaf, Sarina Elmariah, Paul Yanning Jiang, Jennifer Mead, Pamela Hodges, Sarah Elizabeth Valiante, Francesca Mernick, Karl E Anderson, Amy Dickey   +8 more
openaire   +1 more source

Afamelanotide

Reactions Weekly, 2015
openaire   +1 more source

Afamelanotide

Reactions Weekly, 2014
openaire   +1 more source